Patent Cliff Leads Pfizer To Begin Direct Sales To Pharmacies; Aussie Distributors Reeling
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Pfizer Australia will begin direct sales of its prescription medicines to pharmacies in early 2011, cutting out distributors as part of a global battle to go head-to-head against generic copies of blockbuster drugs like Lipitor that face patent expiry in the coming years
You may also be interested in...
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
Pfizer Shake Up Continues With Key Exits From Emerging Markets
In the wake of CEO Jeff Kindler's abrupt departure earlier this week, Pfizer has announced two key departures from its emerging markets team, suggesting greater changes may be on the way at the world's largest drug maker